The Chromatin Remodeling Protein CHD-1 and the EFL-1/DPL-1 Transcription Factor Cooperatively Down Regulate CDK-2 to Control SAS-6 Levels and Centriole Number

Jyoti Iyer^{1#}, Lindsey Gentry², Mary Bergwell¹, Amy Smith¹, Sarah Guargliardo², Peter A. Kropp², Prabhu Sankaralingam², Yan Liu², Eric Spooner³, Bruce Bowerman⁴ and Kevin F. O'Connell^{2#}

¹ Department of Chemistry and Biochemistry, University of Tulsa, Tulsa, OK 74104

² Laboratory of Biochemistry and Genetics, National Institutes of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, MD 20892

³ Proteomics Core Facility, Whitehead Institute for Biomedical Research, Cambridge MA 02142

⁴ Institute of Molecular Biology, University of Oregon, Eugene, OR 97403

Running Title: Transcriptional regulation of *cdk-2* controls centriole assembly.

Keywords: Centriole, transcriptional regulation, Cdk2, E2F, *C. elegans*

Corresponding authors

Abstract

Centrioles are submicron-scale, barrel-shaped organelles typically found in pairs, and play important roles in ciliogenesis and bipolar spindle assembly. In general, successful execution of centriole-dependent processes is highly reliant on the ability of the cell to stringently control centriole number. This in turn is mainly achieved through the precise duplication of centrioles during each S phase. Aberrations in centriole duplication disrupt spindle assembly and cilia based signaling and have been linked to cancer, primary microcephaly and a variety of growth disorders. Studies aimed at understanding how centriole duplication is controlled have mainly focused on the post-translational regulation of two key components of this pathway: the master regulatory kinase ZYG-1/Plk4 and the scaffold component SAS-6. In contrast, how transcriptional control mechanisms might contribute to this process have not been well explored. Here we show that the chromatin remodeling protein CHD-1 contributes to the regulation of centriole duplication in the *C. elegans* embryo. Specifically, we find that loss of CHD-1 or inactivation of its ATPase activity can restore embryonic viability and centriole duplication to a strain expressing insufficient ZYG-1 activity. Interestingly, loss of CHD-1 is associated with increases in the levels of two ZYG-1-binding partners: SPD-2, the centriole receptor for ZYG-1 and SAS-6. Finally, we explore transcriptional regulatory networks governing centriole duplication and find that CHD-1 and a second transcription factor, EFL-1/DPL-1 cooperate to down regulate expression of CDK-2, which in turn promotes

54 SAS-6 protein levels. Disruption of this regulatory network results in the
55 overexpression of SAS-6 and the production of extra centrioles.

56

57

Author Summary

Centrioles are cellular constituents that play an important role in cell reproduction, signaling and movement. To properly function, centrioles must be present in the cell at precise numbers. Errors in maintaining centriole number result in cell division defects and diseases such as cancer and microcephaly. How the cell maintains proper centriole copy number is not entirely understood. Here we show that two transcription factors, EFL-1/DPL-1 and CHD-1 cooperate to reduce expression of CDK-2, a master regulator of the cell cycle. We find that CDK-2 in turn promotes expression of SAS-6, a major building block of centrioles. When EFL-1/DPL-1 and CHD-1 are inhibited, CDK-2 is overexpressed. This leads to increased levels of SAS-6 and excess centrioles. Our work thus demonstrates a novel mechanism for controlling centriole number and is thus relevant to those human diseases caused by defects in centriole copy number control.

Introduction

Centrioles are small cylindrical-shaped protein complexes that function in a variety of important cellular processes[1]. In mitotic cells, a centriole pair recruits a proteinaceous matrix of pericentriolar material, or PCM, to form the primary microtubule-organizing center (MTOC) known as a centrosome. Centrosomes, which possess the ability to nucleate and anchor microtubules, can control cell polarity, organize the poles of the mitotic spindle, and specify the orientation of cell division. In nonmitotic cells, centrioles can serve as basal bodies to organize cilia and flagella, and thus contribute to cell motility and signaling.

One key property of centrioles that is critically important for their proper function, is numerical control[2]. That is, centrioles must be present in cells at precisely defined numbers; typically, one or two pairs depending on the cell cycle stage. Not surprisingly, defects in centriole number and structure have been linked to a growing number of human diseases. It has long been known that many cancers are associated with an excess number of centrioles, and it has recently been shown in a mice that an experimental increase in centriole number can induce tumor formation in many different tissues[3]. Other diseases linked to centriole dysfunction include primordial dwarfism and primary microcephaly [4-6]. The hallmark of primary microcephaly is a small brain size caused by a defect in expansion of neural progenitor cells in the developing neocortex. Interestingly, while microcephaly can arise as a consequence of an insufficient number of

centrioles, it can also arise due to the overproduction of centrioles[7,8], thereby illustrating the critical importance of maintaining proper centriole number during brain development.

Numerical control of centrioles relies upon a single precise duplication event that takes place during each S phase wherein a single daughter centriole is assembled at a perpendicular angle next to each pre-existing mother centriole. The core centriole assembly pathway is broadly conserved and was first elucidated in the nematode *C. elegans*. The master regulator of centriole duplication is a polo-like kinase referred to as ZYG-1 in *C. elegans*, or Plk4 in vertebrates and flies [9,10]. A key event in centriole assembly is the recruitment of ZYG-1 to the site of centriole assembly through a physical interaction with its centriole receptor SPD-2 [11]. ZYG-1 in turn recruits a complex of two proteins, SAS-5 and SAS-6 [12,13] that form the central scaffold that establishes the nine-fold radial symmetry of the centriole [14,15]. This step involves a direct physical interaction between ZYG-1 and SAS-6 [16]. Finally, the microtubule-binding protein SAS-4 is added to the outer wall where it promotes the assembly of the centriolar microtubules [12,13].

How centriole assembly is restricted to avoid an excess number of centrioles has been an active area of research. Numerous studies have demonstrated the need to control the abundance of centriole assembly factors, as experimental overexpression of ZYG-1/Plk4, SAS-5/STIL or SAS-6 results in the formation of extra centrioles [17-23]. To date, most of the mechanisms that have been described

function post-translationally to limit the levels of these factors via ubiquitin-mediated degradation (reviewed in [24]).

However, we and others have also demonstrated that the abundance of centriole assembly factors is regulated at a transcriptional level. In particular, members of the E2F family of transcription factors play both positive and negative roles in regulating centriole assembly in vertebrates and invertebrates [25-29]. The E2F transcription factors are obligate heterodimers containing one E2F protein and one DP protein (EFL and DPL respectively in *C. elegans*) [30]. In *C. elegans*, EFL-1 is most closely related to vertebrate E2F4 and E2F5, which primarily act to repress transcription of target genes. Together with DPL-1, the sole *C. elegans* DP protein, EFL-1 negatively regulates centriole assembly, as loss of this transcription factor results in elevation of SAS-6 protein levels and suppression of the centriole assembly defect in animals compromised for ZYG-1 function [27]. EFL-1/DPL-1, however, does not act directly by negatively regulating transcription of the *sas-6* gene [27] and thus how its loss results in elevation of SAS-6 protein levels remains an open question. While E2F-dependent pathways appear to predominate in the transcriptional control of centriole assembly, E2F-independent pathways are likely to exist.

CHD1 (chromodomain helicase DNA-binding protein 1) is a highly conserved chromatin remodeler that arranges nucleosomes at regular intervals across gene bodies in an ATP-dependent manner [31,32]. CHD1 has chiefly been implicated in

regulating transcriptional elongation [33-38] but evidence has emerged suggesting that it also plays a role in transcriptional initiation [39-41] and termination [42-44]. Outside of its known roles in regulating gene expression, CHD1 has also been shown to function in DNA repair [45], sister chromatid cohesion [46], and histone modification [35,47]. CHD1 possesses two tandem chromodomains at its N-terminus that selectively bind lysine 4-methylated histone H3 of nucleosomes within transcriptionally-active chromatin [48,47,49], a central SNF2-like ATPase/helicase domain and a C-terminal SANT/SLIDE DNA-binding domain. In humans, CHD1 functions as a tumor suppressor and is the second most frequently deleted gene in prostate cancers [50].

Several lines of evidence suggest that CHD1 might be involved in regulating centriole duplication and/or function. Firstly, CHD1 localizes to the promoters of centrosome genes in mouse and human embryonic stem cells [51,52]. Secondly, CHD1 physically associates with the *Xenopus* ZYG-1 ortholog [53], and finally, *chd1-null* flies have spindle and astral microtubule defects [54]. Here we investigate a role for the *C. elegans* CHD1 protein (CHD-1) in regulating centriole duplication and find that complete loss of CHD-1 or inactivation of its ATPase activity, partially suppresses both the embryonic lethality and centriole duplication defects caused by a hypomorphic *zyg-1* mutation. Loss of CHD-1 is also associated with an increase in the levels of the ZYG-1-binding proteins SPD-2 and SAS-6, likely providing a mechanism for suppression. We present evidence that CHD-1 does not regulate transcription of the *sas-6* gene, but rather negatively regulates CDK-2, which in turn

promotes SAS-6 protein levels. We also find that EFL-1/DPL-1 acts in parallel to CHD-1 to downregulate CDK-2, and that the combined loss of both factors leads to further elevation of SAS-6 levels and the appearance of extra centrosomes and multipolar spindles. Our results thus reveal how two transcriptional regulatory pathways are integrated with a CDK-2-dependent mechanism that post-translationally controls SAS-6 expression and centriole number.

Results

Loss of CHD-1 partially restores centriole duplication in a *zyg-1* hypomorphic mutant

The existing literature in frogs, flies, mice and humans collectively suggests that CHD-1 plays a role in regulating centriole duplication. Therefore, we first set out to determine if CHD-1 is essential for regulating centriole number by obtaining an existing *chd-1* partial deletion allele from the *Caenorhabditis* Genetics Center (CGC). The *chd-1(ok2798)* allele deletes the C-terminal 197 amino acids encompassing the helicase and DNA-binding domains (Figure 1A), and thus most likely represents a strong loss of function, if not a molecular null. Animals homozygous for the *chd-1(ok2798)* allele are viable, fertile and lack any obvious morphologic or behavioral defects. Further, nearly all progeny produced by homozygous mutant mothers are viable (98.5 % viable n=12 hermaphrodites, 3291 embryos). This is in contrast to all known mutations that block centriole duplication; in such cases, mutants exhibit a maternal-effect embryonic lethal phenotype and/or a sterile uncoordinated phenotype due to cell division failures in the embryonic or postembryonic tissues respectively [55]. The absence of embryonic lethal and sterile phenotypes indicates that CHD-1 is non-essential in worms, and thus, is not required for centriole duplication.

While our results show that CHD-1 is not a key component of the centriole duplication pathway, it still might play an accessory role. To investigate this, we

asked if the loss of CHD-1 could modify the phenotype of a *zyg-1(it25)* mutant. The *zyg-1(it25)* allele is a hypomorphic missense mutation that confers a temperature-sensitive block to centriole assembly in early embryos; as a result, at the restrictive temperature of 24°C, 100 percent of the embryos die. To determine if CHD-1 plays a role in centriole duplication, we first monitored the embryonic viability of *zyg-1(it25)* mutants and *chd-1(ok2798); zyg-1(it25)* double mutants grown at the semi-restrictive temperature of 23.5°C. At this temperature, *zyg-1(it25)* mutants exhibited a very low level of embryonic viability (Figure 1B). In contrast, about half of the progeny of the *chd-1(ok2798); zyg-1(it25)* double mutants were viable. These data indicate a potential role for CHD-1 in regulating centriole duplication. We then analyzed centriole duplication in the *zyg-1(it25)* single and *chd-1(ok2798); zyg-1(it25)* double mutants by DIC live imaging. Although all centrioles failed to duplicate in *zyg-1(it25)* single mutants (n=12 centrosomes), centrioles duplicated 64% of the time in the *chd-1(ok2798); zyg-1(it25)* double mutants (n=14 centrosomes). Thus, loss of CHD-1 activity is able to partially restore proper centriole duplication in a ZYG-1-deficient strain.

While the *chd-1(ok2798)* deletion is almost certainly a null allele, it still retains the N-terminal chromodomains. To unambiguously establish the null phenotype and to investigate CHD-1 function further, we created two knock out alleles using CRISPR-Cas9 genome editing. We first replaced the *chd-1* open reading frame with superfolder GFP (sfGFP), allowing us to both verify the complete loss-of-function phenotype and to determine the tissue-specific expression pattern

of CHD-1. We refer to this allele as *chd-1(bs122)*. Western blotting of *chd-1(bs122)* worm extracts with an anti-GFP antibody detected a single band close to 30 kDa, the approximate molecular weight of sfGFP, indicating that the 5' and 3' flanking regions of *chd-1* are sufficient to drive sfGFP expression (Figure 1C). The second allele, *chd-1(bs185)*, deletes nearly the entire *chd-1* ORF, leaving a sequence that encodes just the first nine and last two amino acids; this allele was used in imaging experiments where the GFP produced by the *chd-1(bs122)* allele would have complicated image analysis. Like *chd-1(ok2798)* animals, *chd-1(bs122)* animals are fertile and wild-type in appearance. Further, they do not exhibit embryonic lethality when grown over a range of temperatures (Figure S1A). Surprisingly however, *chd-1(bs122)* animals exhibit a cold-sensitive reduction in brood size (Figure S1B). At 25°C, both wild-type and *chd-1(bs122)* animals produce on average approximately 300 offspring. However, at 20°C where wild-type animals produce an average of 310 offspring, *chd-1(bs122)* animals produce only an average of 255. This difference is exacerbated at 16°C where wild-type hermaphrodites produce an average of 303 offspring and *chd-1(bs122)* hermaphrodites produce only an average of 195. Thus CHD-1 is required for normal fecundity at low temperatures.

We next tested how a complete loss of *chd-1* affects the embryonic lethality and centrosome duplication defects of a *zyg-1(it25)* mutant. When introduced into a *zyg-1(it25)* strain, the *chd-1(bs122)* allele suppressed the embryonic lethality observed at semipermissive temperature (Figure 1D); while *zyg-1(it25)* single mutants produce on average only three percent viable offspring, an average of 70

percent of the offspring of *chd-1(bs122); zyg-1(it25)* double mutants survive. To monitor centriole duplication, we performed time-lapse spinning disk confocal imaging of embryos produced by *zyg-1(it25)* and *chd-1(bs185); zyg-1(it25)* hermaphrodites expressing sfGFP::histone and SPD-2::mCherry (Figure 1D and 1E). While all centrioles (n=34) failed to duplicate in *zyg-1(it25)* single mutant embryos, 27 percent of the centrioles (n=55) duplicated in *chd-1(bs185); zyg-1(it25)* double mutant embryos. Thus, a complete loss of CHD-1 partially suppresses both the embryonic lethality and centriole duplication defects of the *zyg-1(it25)* mutant, indicating that the presence of CHD-1 somehow normally inhibits the ability of centrioles to duplicate.

CHD-1 is a broadly expressed nuclear protein that is down-regulated in oocytes and embryos

To gain insight into how CHD-1 might regulate centriole duplication, we sought to determine its expression pattern and subcellular distribution. We first analyzed *chd-1(bs122)* worms, where sfGFP expression is entirely controlled by the *chd-1* cis-acting elements (promoter and 3' utr). We observed broad expression throughout worms including in the germ line and somatic tissues (Figure 2B, top panel). The broad expression pattern in worms is consistent with that of the human ortholog which was found to be expressed in many different tissues [38]. Interestingly, while sfGFP was evenly diffuse in somatic cells and the distal germ line, it concentrated strongly in the nuclei of oocytes and early embryonic cells. While we do not currently understand why sfGFP concentrates in these specific

nuclei, our results clearly show that the *chd-1* gene is broadly expressed in the worm.

We next fused sfGFP to the 3' end of the endogenous *chd-1* orf using CRISPR-Cas9 genome editing (Figure 2A). This allele which we named *chd-1(bs125)* expressed a single protein of the expected size on immunoblots, although the band intensity is very dim suggesting that CHD-1 is a low abundance protein (Figure 2C). To determine if CHD-1::sfGFP was functional, we crossed this allele into the *zyg-1(it25)* background and monitored embryonic viability. If the sfGFP tag interferes with the function of CHD-1, we would expect that *chd-1(bs125)* would behave as a loss-of-function allele and suppress the embryonic lethality of the *zyg-1(it25)* mutant. However, this was not the case, as *chd-1(bs125); zyg-1(it25)* animals exhibited low levels of embryonic viability (Figure 2D) that were comparable to those of the *zyg-1(it25)* single mutant (Figure 1B). We imaged CHD-1::sfGFP worms and found that CHD-1::sfGFP was enriched in nuclei throughout the worm (Figure 2B, bottom panel). This included all germ-line nuclei and many somatic cells such as the intestinal cells and cells of the pharynx and somatic gonad. At a subcellular level, the only structure in which we detected CHD-1 enrichment was the nucleus. Importantly, we did not detect localization to centrosomes. While CHD-1::sfGFP expression was detected in oocyte nuclei, the levels were lower than other germ-line nuclei. Interestingly, we could not detect expression in early embryos (Figure 2B, bottom panel), suggesting that CHD-1 does not directly regulate centriole

duplication in the embryo but instead may function in the maternal germ line to control gene expression.

The helicase activity of CHD-1 is required for regulation of centriole duplication

Next, we sought to determine the molecular mechanism by which CHD-1 regulates centriole duplication. Since *Xenopus* CHD-1 has been reported to physically interact with the frog ZYG-1 homolog [53], we used Immunoprecipitation (IP) followed by mass spectrometry to determine if such an interaction exists in worms. Although we identified several proteins that were specifically enriched in the CHD-1 immunoprecipitate (Table S1), including the putative worm ortholog of CNBP, an RNA Pol II regulator, we were unable to identify an interaction between CHD-1 and any of the known centriole assembly factors including ZYG-1. These results suggest that CHD-1 regulates centriole duplication through a more indirect mechanism.

The best characterized function of CHD-1 is that of a chromatin remodeling protein. Therefore, we wondered whether CHD-1 could affect centriole duplication by modulating gene expression. As a means to address this question, we sought to engineer an ATPase-inactive version of CHD-1, since the ability of CHD-1 to remodel chromatin is ATP dependent [56]. As the crystal structure of *C. elegans* CHD-1 is not available, we predicted *C. elegans* CHD-1 structure using Swiss Model and aligned it to the available crystal structure of yeast CHD-1 [57]. From this alignment we

identified residue D538 of worm CHD-1 as corresponding to aspartate 513 within the Walker B motif of yeast CHD1 (Figure 2E). This residue is critical for activation of the helicase ATPase [57]. We then used CRISPR-Cas9 genome editing to create the *chd-1(bs123)* allele, which encodes CHD-1(D538N)::sfGFP (Figure 2A). To determine if the ATPase activity of CHD-1 is important for its function in centriole duplication, we created a *chd-1(bs123); zyg-1(it25)* double mutant. Significantly, we found that expression of the ATPase inactive CHD-1 mutant suppressed the embryonic lethal phenotype of *zyg-1(it25)* mutants, indicating that the ATPase activity of CHD-1 is important for its role in regulating centriole duplication (Figure 2D). The ability of the *chd-1(bs123)* mutation to suppress *zyg-1(it25)* was not due to altered expression of the ATPase-inactive form of CHD-1::GFP as quantitative western blotting indicated that CHD-1(D538N)::sfGFP and CHD-1::sfGFP are expressed at similar levels (Figure 2C). Suppression was also not the result of mis-localization of CHD1(D538N)::sfGFP, as the CHD-1(D538N)::sfGFP protein exhibited a similar localization pattern to that of wild-type CHD-1::sfGFP (Figure S2). Collectively, these data indicate that CHD-1 ATPase activity is specifically required for its role in regulating centriole duplication, suggesting that CHD-1 most likely functions to regulate transcription.

Loss of CHD-1 results in the upregulation of SAS-6 and SPD-2 protein levels

One mechanism through which loss of CHD-1 activity might suppress the *zyg-1(it25)* centriole duplication defect could involve upregulation of centriole assembly factors, as we previously showed that *zyg-1(it25)* strains expressing elevated levels

of ZYG-1 itself, or SAS-6 are able to duplicate their centrioles [27,58]. We therefore sought to determine if the levels of ZYG-1, SPD-2, SAS-5 or SAS-6 were altered in worms carrying the *chd-1(bs122)* null allele. As ZYG-1 is difficult to detect on immunoblots, we used quantitative fluorescence to measure ZYG-1 levels at centrioles in wild-type and *chd-1(bs122)* mutants; for this we employed an epitope tagged version of the endogenous *zyg-1* gene (*spot::zyg-1*). As shown in Figure S3A, the level of ZYG-1 at the centrosome was slightly but significantly elevated in the *chd-1(bs122)* mutant relative to the wild type. While overexpression of *zyg-1* could certainly contribute to the *chd-1*-mediated suppression of *zyg-1(it25)*, the magnitude of this effect suggested that another mechanism was primarily responsible for suppression. We therefore measured the levels of the other centriole assembly factors by quantitative immunoblotting and surprisingly found that SAS-5 protein levels are reduced in *chd-1(bs122)* mutant relative to the wild type (Figure S3B). While unexpected, this result rules out the possibility that the suppression observed upon loss of CHD-1 is due to overexpression of SAS-5. Finally, we analyzed SPD-2 and SAS-6 and found that the levels of both proteins are elevated in *chd-1(bs122)* worms (Figure 3A and 3B). SPD-2 was found to be elevated almost two-fold in the absence of CHD-1, while SAS-6 was elevated approximately three-fold (Figure 3C). We also found that SPD-2 levels were unaffected in the *chd-1(bs125[chd-1::sfGFP])* strain consistent with our finding that CHD-1::sfGFP is functional (Figure 3A). Thus, the two known ZYG-1-binding proteins, SPD-2 and SAS-6, are expressed at higher levels in *chd-1* null mutants.

The level of SPD-2 at centrosomes is elevated in the absence of CHD-1

To confirm and extend these results we sought to examine the levels of SAS-6 and SPD-2 at centrosomes in control and *chd-1(bs122)* embryos. We first examined endogenous SAS-6 by immunofluorescence in an isogenic pair of wild-type and *chd-1(bs122)* strains carrying a spot-tagged version of *sas-6*. As shown in figure S4, we detected a slight increase in the average intensity of SPOT::SAS-6 at centrosomes in the *chd-1(bs122)* mutant relative to controls. However, this increase did not prove to be significant, indicating that the increase in overall levels of SAS-6 in the *chd-1(bs122)* mutant does not necessarily translate into higher levels of SAS-6 at the centrosome.

For measuring SPD-2 levels at the centrosome, we initially employed a *gfp::spd-2* transgene driven by the *pie-1* promoter and 3'utr. Contrary to our expectations, we found that GFP::SPD-2 fluorescence intensity at the centrosome was strongly reduced in *chd-1(bs122)* homozygotes compared to their heterozygous siblings (Figure 3D). In fact, most (58%, n=52) of the *chd-1(bs122)* embryos lacked detectable GFP::SPD-2 expression. When these same embryos were analyzed by quantitative immunoblotting, we found a reduction in the level of GFP::SPD-2 protein and a corresponding increase in the level of endogenous SPD-2 (Figure 3E). We suspect two independent mechanisms that regulate SPD-2 expression account for this result. First, CHD-1 likely inhibits SPD-2 expression directly or indirectly through the 5'- and/or 3'-flanking regions of the *spd-2* gene. Since these elements are absent in the *gfp::spd-2* transgene, loss of CHD-1 would not be expected to elevate GFP::SPD-2 expression. Second, as shown by Decker et al., [59], *C. elegans*

embryos possess a homeostatic mechanism that helps maintain SPD-2 levels within a specified range. Thus, we envision that loss of CHD-1 relieves an inhibitory mechanism that operates through the *spd-2* flanking regions resulting in over-expression of the endogenous gene. In response to increased SPD-2, the homeostatic control mechanism attempts to decrease overall SPD-2 levels. This set of events would result in a net increase of endogenous SPD-2 and a net decrease of GFP::SPD-2 in the *chd-1(bs122)* strain. To test this idea, we analyzed the levels of a *spd-2::mcherry* transgene in control and *chd-1(bs122)* embryos; in contrast to the *gfp::spd-2* transgene, expression of the *spd-2::mcherry* transgene is driven by the endogenous *spd-2* flanking regions. As shown in Figure 3F, the response of this transgene to the absence of CHD-1, was distinctly different from the *pie-1*-driven construct; relative to controls, SPD-2::mCherry fluorescence at the centrosome is elevated in *chd-1(bs122)* embryos. We conclude that CHD-1 inhibits expression of SPD-2 in a manner that is dependent on the *spd-2* promoter and/or 3' utr. Conversely, our results also demonstrate that homeostatic control of SPD-2 is independent of the 5'- and 3'-flanking regions.

CHD-1 does not regulate *sas-6* or *spd-2* transcript levels.

So far, our work shows that SAS-6 and SPD-2 proteins are significantly upregulated in the absence of CHD-1. To determine if CHD-1 controls the abundance of *sas-6* or *spd-2* transcript levels, and to determine what other genes might be regulated by CHD-1, we performed RNA-Seq on whole adult worms. Consistent with studies in yeast [60,61], we found that in *C. elegans* only a few genes

were strongly affected by loss of CHD-1; specifically, expression of just 11 genes differed by two-fold or more between *chd-1(bs122)* and wild-type worms (Figure 4A), but none of the genes in this set are known to function in centriole assembly. We therefore further analyzed this data set by assigning a p value of less than 0.05 as a cut off and found that the transcript levels of approximately 2200 genes were weakly altered in the mutant (Tables S2 and S3). Surprisingly, none of the genes encoding centriole duplication factors were among this group. To confirm our RNA-Seq results, we used qRT-PCR to compare the levels of *sas-6* and *spd-2* transcripts in wild-type and *chd-1(bs122)* worms. Consistent with our RNA-Seq results, qRT-PCR analysis revealed that loss of CHD-1 did not affect the transcript levels of either gene (Figure 4B). Together, our data indicate that CHD-1 does not regulate expression of *spd-2*, *sas-6*, or any other known core centriole assembly factor at the level of transcription or message stability.

CHD-1 and EFL-1/DPL-1 function independently to control SAS-6 abundance and centriole number

As shown in a prior study, overexpression of SPD-2 is not sufficient to suppress *zyg-1(it25)* embryonic lethality [58]. We thus reasoned that the elevated level of SAS-6 observed in *chd-1* mutants is primarily responsible for rescue of the *zyg-1(it25)* centriole duplication defect. This idea is consistent with our prior work demonstrating that loss of the heterodimeric transcription factor EFL-1/DPL-1 results in the upregulation of SAS-6 protein levels and suppression of *zyg-1(it25)* [27]. Interestingly, our prior work also showed that EFL-1/DPL-1, like CHD-1, does

not repress SAS-6 expression by regulating *sas-6* transcript levels. We thus wondered if CHD-1 and EFL-1/DPL-1 function in the same pathway to regulate SAS-6 and centriole duplication. If so, the effect of knocking out both transcription factors should not be greater than the effect of knocking out either factor individually. Therefore, we asked if depleting DPL-1 would enhance suppression of the embryonic lethal phenotype in a *chd-1(bs122); zyg-1(it25)* strain. We performed this assay at 24° where *chd-1(bs122)* suppression was relatively weak, so that any enhancement of suppression could be easily detected. As shown in Figure 5A, under our conditions, RNAi of *dpl-1* in either a wild-type or *zyg-1(it25)* mutant background did not alter the level of embryonic viability relative to RNAi of the nonessential gene *smd-1*, which served as a negative control. Since, it has previously been established that loss of DPL-1 significantly decreases embryonic viability in wild-type worms [36,44] and increases embryonic viability in *zyg-1(it25)* worms [29,34], the lack of an effect in either genetic background indicates that RNAi-based depletion of DPL-1, as employed here, is weak. Despite this, when *chd-1(bs122); zyg-1(it25)* worms were treated with *dpl-1(RNAi)*, they exhibited a significant boost in embryonic viability compared to controls (52% vs 6% respectively; Figure 5A). Thus, loss of EFL-1/DPL-1 enhances the ability of a *chd-1* null allele to suppress *zyg-1(it25)*, arguing that these two factors likely function independently to control centriole duplication.

Our results show that loss of either CHD-1 or EFL-1/DPL-1 leads to increased levels of SAS-6. Since our genetic analysis suggests that these factors function in

different pathways, we hypothesized that loss of both factors would lead to an even higher level of SAS-6 that could result in centriole amplification as seen when SAS-6 is overexpressed in other systems[20,21,62]. To address this possibility, we investigated if *chd-1* and *dpl-1* genetically interact in an otherwise wild-type background. As shown in Figure 5B, RNAi-based depletion of DPL-1 in a wild-type background had no effect on embryonic viability (compare *smd-1(RNAi)* vs *dpl-1(RNAi)*). However, in a *chd-1(bs122)* background, *dpl-1(RNAi)* led to a dramatic decrease in embryonic viability with about half of the embryos failing to hatch (compare *chd-1; smd-1(RNAi)* to *chd-1; dpl-1(RNAi)*). Thus, *chd-1* and *dpl-1* genetically interact.

As mentioned above, *dpl-1(RNAi)* is inefficient. Thus, we wondered if a stronger genetic interaction might be identified using a loss-of-function allele of *dpl-1*. The *dpl-1(bs21)* allele identified in our genetic screen is a nonsense mutation (Q521X) that results in truncation of the last 196 amino acid residues while leaving the DNA-binding and heterodimerization domains intact. The *dpl-1(bs21)* allele behaves as a hypomorph and confers a partial embryonic lethal phenotype [63,27]. Using CRISPR-Cas9 genome editing we recreated this allele which we named *dpl-1(bs169)*. We then quantified the effect of this allele on embryonic viability either alone or in the presence of the *chd-1(bs122)* allele over a range of temperatures (Figure 5C). Surprisingly we found that *dpl-1(bs169)* confers a cold-sensitive embryonic lethal phenotype. Hermaphrodites, carrying the *dpl-1(bs169)* mutation exhibit relatively high embryonic viability (66%) at 25° but progressively lower

embryonic viability as the temperature is decreased (46% at 20°, 25% at 16°, and 8% at 12.5°). Strikingly, hermaphrodites carrying both the *chd-1(bs122)* and *dpl-1(bs169)* alleles consistently display lower embryonic viability than the *dpl-1(bs169)* single mutants at all temperatures tested (22% at 25°, 14% at 20°, 3% at 16°, and 0% at 12.5°). The increased embryonic lethality observed in the double mutant is not due to an additive effect, as the *chd-1(bs122)* allele does not produce an embryonic lethal phenotype on its own at any of the temperatures tested. Thus, the loss of CHD-1 enhances the embryonic lethal phenotype of a *dpl-1* loss-of-function allele, suggesting that overexpression of SAS-6 is toxic.

Previously, we have shown that a small percentage of embryos produced from *dpl-1(bs21)* hermaphrodites possess extra centrosomes [27]. This analysis however was performed at elevated temperature where the *dpl-1(bs21)* allele is still relatively active. Thus, we sought to determine how loss of either EFL-1/DPL-1 alone or the combined loss of both CHD-1 and EFL-1/DPL-1 affects centriole duplication under the most restrictive of conditions. Single and double mutants were grown at 12.5° and embryos immunostained with antibodies to alpha-tubulin and the centrosome marker CeGrip1 (aka GIP-1) [64]. As shown in Figure 5D, among the offspring of both *dpl-1(bs169)* single mutants and *chd-1(bs122); dpl-1(bs169)* double mutants, we observed embryos with supernumerary centrosomes. Although cytokinesis defects are a known source of extra centrosomes, such a defect does not appear to account for the emergence of extra centrosomes in these mutants. Cytokinesis failure invariably gives rise to an even number of centrosomes whereas

we observed numerous cases of cells with an odd number of centrosomes (Figure 5D). Furthermore, we did not observe other hallmarks of cytokinesis failure such as binucleate cells. Thus, the extra centrosomes most likely arise through an over-production mechanism (e.g. overduplication or *de novo* assembly of centrioles).

Analysis of the cellular distribution and frequency of extra centrosomes among the single and double mutant embryos revealed additional details of this defect (Table 1). First, no extra centrosomes were observed at the one-cell stage in either single or double mutants. As the zygote's centrioles are of paternal origin, such a defect at this stage of development would indicate a defect in the male germ line. Thus, the absence of such defects suggests that loss of EFL-1/DPL-1 alone or both CHD-1 and EFL-1/DPL-1 selectively affects maternal control of centriole assembly. Second, the *chd-1(bs122)* null allele strongly enhances the extra-centrosome defect of the *dpl-1(bs169)* mutant; only two out of 120 cells from young (two-six-cell stage) *dpl-1(bs169)* embryos possessed one or more extra centrosomes while 22 out of 125 cells from similarly staged *chd-1(bs122); dpl-1(bs169)* embryos exhibited this defect. The difference is highly significant ($p < 0.0001$) indicating that loss of *chd-1* strongly enhances the centrosome amplification defect of the *dpl-1* mutant.

514

Table 1: Loss of *chd-1* enhances the multipolar spindle defect of the *dpl-1(bs169)* mutation

	Genotype	
	<i>dpl-1(bs169)</i>	<i>chd-1(bs122); dpl-1(bs169)</i>
Total embryos scored	64	70
Total one-cell embryos scored	18	22
Multipolar one-cell embryos	0	0
Total 2-6 cell stage embryos scored	46	48
Multipolar 2-6-cell stage embryos	2	18
Total cells of 2-6 cell stage embryos	120	125
Multipolar cells of 2-6 cell stage embryos*	2	22

515 * Chi-squared analysis, p=0.000027

516

517

518 **CHD-1 and EFL-1/DPL-1 independently down-regulate CDK-2 activity to**
519 **control SAS-6 abundance.**

520

521 Recent work has shown that EFL-1/DPL-1 down regulates transcription of
522 the *cdk-2* gene in the *C. elegans* germ line [65]. CDK-2 is required for centriole
523 duplication in vertebrates [66-68,26] and has recently been shown to protect the
524 SAS-6 binding partner STIL/SAS-5 from degradation mediated by the SCF^{βTrCP} E3
525 ubiquitin ligase [69]. Therefore, we wondered if CDK-2 might be the relevant target
526 of EFL-1/DPL-1 and possibly CHD-1 as well. Consistent with such a mechanism, we
527 found that *cdk-2* transcripts are upregulated in the *chd-1(bs122)* mutant relative to
528 the control strain (Figure 4B). Thus, both CHD-1 and EFL-1/DPL-1 independently

down regulate *cdk-2* expression. We also noticed that *cki-2*, a CDK-2 inhibitor whose down regulation has been reported to result in the presence of supernumerary centrosomes [70], was among the set of genes weakly down regulated in the *chd-1* deletion strain (Supplementary Table S2). However, qRT-PCR analysis revealed that the level of *cki-2* transcripts is unaffected by the *chd-1(bs122)* mutation (Figure 4B). In summary, our data suggest a model whereby the loss of either transcriptional regulator results in elevated levels of CDK-2 activity, which in turn, acts post-transcriptionally to promote SAS-6 expression.

We set out to test our hypothesis by determining if CDK-2 was required for suppression of the embryonic lethality of a *zyg-1(it25)* mutant by loss of either EFL-1/DPL-1 or CHD-1. As demonstrated above, *zyg-1(it25)* animals grown at the nonpermissive temperature of 24°C do not produce any viable progeny (Figure 5A, *zyg-1(it25); smd-1(RNAi)*). In contrast, *zyg-1(it25) dpl-1(bs169)* double mutants grown under identical conditions produce approximately 80% viable offspring (Figure 6A), demonstrating the ability of the *dpl-1(bs21)* mutation to robustly suppress the lethality of the *zyg-1(it25)* allele. Strikingly, when the double mutant was treated with *cdk-2(RNAi)* there was almost a complete loss of viability among the offspring of the *zyg-1(it25) dpl-1(bs169)* double mutants. Importantly, depletion of *cdk-2* only mildly affected embryonic viability in wild-type animals, indicating that the nearly complete loss of viability observed in *zyg-1(it25) dpl-1(bs169)* animals exposed to *cdk-2(RNAi)* was due to a loss of suppression rather than disruption of an essential CDK-2-dependent function. We performed the same

experiment with the *chd-1(bs122); zyg-1(it25)* double mutant and found that at the semipermissive temperature of 23.5°C, *chd-1(bs122)*-mediated suppression of *zyg-1(it25)* was also reduced upon *cdk-2(RNAi)* (Figure 6B). However, CDK-2 depletion only partially eliminated suppression by the *chd-1(bs122)* allele, suggesting that CHD-1 might regulate centriole duplication through additional mechanisms that do not involve CDK-2.

We next used quantitative western blotting to determine if CDK-2 controls the level of SAS-6. For these experiments, we employed the auxin inducible degradation system [71] to robustly deplete CDK-2. We therefore constructed a strain harboring an endogenous *cdk-2* gene tagged with the auxin-inducible degron (AID) and carrying a transgene that expresses the substrate recognition component TIR1 in the germ line. This strain was grown in the absence and presence of 1 mM auxin. As shown in Figures 6C and 6D, upon treatment with auxin SAS-6 dropped to an undetectable level, consistent with a role for CDK-2 in promoting SAS-6 protein levels.

In summary, our work strongly supports a model (Figure 6E) whereby CHD-1 and EFL-1/DPL-1 function in the maternal *C. elegans* germ line to negatively regulate expression of CDK-2 at the mRNA level. In turn, CDK-2 promotes expression of SAS-6, and when overexpressed can drive the formation of extra centrioles and multipolar spindles.

Discussion

575
576   The cyclin-dependent kinase CDK-2 and members of the E2F family of
577 transcriptional activators have long been known to regulate centriole number in
578 dividing vertebrate cells. In both *Xenopus* eggs and mammalian somatic cells,
579 inhibition of CDK-2 complexed with either cyclin A or cyclin E blocks centriole
580 assembly [66-68,26]. In contrast, E2F members can play either positive or negative
581 roles in centriole biogenesis. DP1, E2F2 and E2F3 have been shown to promote
582 centriole duplication in Chinese hamster ovary cells [26], while loss of E2F3 results
583 in centriole amplification in mouse embryonic fibroblasts [29]. While these
584 pioneering studies hinted that E2F proteins might exert control over centriole
585 assembly by regulating CDK-2 activity, they did not provide definitive proof for such
586 a model. Further, beyond establishing an essential role for CDK-2 in centriole
587 assembly, this early work did not define its mechanism of action.

588
589   Our work builds upon these earlier studies by identifying two parallel
590 transcriptional control pathways—one E2F-dependent and one E2F-independent—
591 that converge upon CDK-2 to limit expression of SAS-6 and ensure a precise
592 doubling of centrioles in the *C. elegans* embryo. As shown by Furuta et al., EFL-
593 1/DPL-1 directly down regulates transcription of CDK-2 [65]. Likewise, we find
594 that CHD-1 represses expression of CDK-2, although it is not yet clear if it does so
595 through a direct or indirect mechanism. Nevertheless, our work shows that the two
596 transcriptional regulators fine tune the level of CDK-2 which in turn regulates the

abundance of the centriole scaffold protein SAS-6 to ensure centriole number is properly maintained.

While EFL-1/DPL-1 and CHD-1 both regulate SAS-6 levels, the two pathways differ in two respects. First, the EFL-1/DPL-1-dependent pathway clearly plays the predominant role in regulating centriole assembly. As our data shows, a hypomorphic *dpl-1* allele more strongly suppresses the centriole duplication defect of *zyg-1(it25)* mutants than a complete deletion of *chd-1*. Further, *dpl-1* mutant embryos possess extra centrosomes whereas *chd-1* null embryos do not. A second distinction between the two pathways is the degree to which they depend on CDK-2 for regulating centriole duplication. Upon *cdk-2(RNAi)*, *zyg-1(it25); dpl-1(bs169)* hermaphrodites produce very few viable offspring, indicating that regulation of centriole duplication by EFL-1/DPL-1 is mostly if not entirely dependent on CDK-2 activity. In contrast, a substantial fraction of the offspring of *chd-1(bs122); zyg-1(it25)* hermaphrodites subjected to *cdk-2(RNAi)* remain viable, suggesting that CHD-1 also regulates centriole duplication in a CDK-2-independent manner.

One exciting possibility is that CHD-1 also functions to regulate centriole assembly outside of its role as a chromatin regulator. Hatch et al., [53] reported a physical interaction between Chd1 and PLK4 in *Xenopus*. While we were unable to establish such an interaction in *C. elegans*, we could have missed this if it were a transient interaction or if it only occurred in a specific subset of cells. Intriguingly, there is a precedent for a transcriptional regulator playing a direct role in centriole

assembly. In multiciliated cells, E2F4 the ortholog of EFL-1 promotes expression of centriole assembly genes before being translocated to the cytoplasm where it forms apical aggregates containing SAS-6 and deup1, a component of ring-shaped protein complexes called deuterosomes that serve as sites of centriole assembly [28]. Remarkably, mutations that block nuclear export of E2F4 allow transcriptional activation of centriole genes but block deuterosome assembly and centriole amplification [28].

Our finding that disruption of both EFL-1/DPL-1 and CHD-1 function leads to elevated SAS-6 levels and the frequent appearance of supernumerary centrosomes, once again highlights how numerical control depends upon the abundance of core centriole assembly factors. Prior work has shown that regulated proteolysis plays a critical role by controlling the levels of ZYG-1/Plk₄, SAS-5/STIL and SAS-6 [69,71,72-78,62]. The basic theme that arises from these studies is that degradation is mediated by an E3 ubiquitin ligase (either SCF or the APC/C), and that temporal control is achieved by regulating substrate recognition through cell-cycle-stage-dependent phosphorylation of either the target protein itself or of the E3 ligase. It therefore seems likely that CDK-2 functions in a similar capacity to control the levels of STIL in vertebrates and SAS-6 in worms. However, in both cases the substrate phosphorylated by CDK-2 remains to be identified.

The question of CDK-2 action notwithstanding, our work, together with that of Arquint et al. 2018 [69], shows that in both worms and humans, CDK-2 regulates

centriole assembly by controlling the abundance of centriole scaffold components. In human cells, CDK-2 stabilizes STIL/SAS-5, a binding partner of SAS-6, by blocking degradation via the E3 ubiquitin ligase SCF^{βTrCP}. In worms, the target of CDK-2 is SAS-6, suggesting an evolutionary divergence of the underlying mechanism. However, the extent to which the mechanisms operating in humans and worms differ is not yet clear. For instance, in humans, SAS-6 levels are also controlled by SCF^{βTrCP}, but whether CDK-2 also regulates SAS-6 abundance has not been investigated. Conversely in worms, SCF^{βTrCP} has been shown to regulate centriole duplication by controlling ZYG-1 levels at the centriole [79], but whether SCF^{βTrCP} also regulates SAS-6 is an open question. Thus, it remains possible that the CDK-2-dependent pathways operating in vertebrates and worms are not all that different.

Over the past two decades research has uncovered a strong link between centriole amplification and human diseases including cancer and primary microcephaly. Interestingly E2F proteins have been implicated in both diseases [80,81], although in neither disease has a link between loss of E2F activity and centriole amplification been established. Our work showing that a loss of EFL-1/DPL-1, or the combined loss of EFL-1/DPL-1 and CHD-1 leads to the presence of extra centrosomes in the *C. elegans* embryo is thus relevant to understanding how these diseases might arise in response to a loss of numerical control.

Materials and Methods

Worm strains and maintenance

Worms were maintained on MYOB agar plates seeded with *E. coli* OP50 at 20°C according to standard protocols [82]. Strains used in this study are described in Table S4.

CRISPR-Cas9 Genome editing

CRISPR-Cas9 genome editing was performed by microinjection of *in-vitro* assembled ribonucleoprotein complexes essentially as previously described [83,84] . Screening utilized the co-CRISPR strategy [85]. The crRNAs were purchased from Dharmacon, Inc. (Lafayette, CO) and primers and oligonucleotide repair templates were purchased from Integrated DNA technologies (Coralville, IA). Cas9 protein was purified according to the protocol by Paix et al, 2015 [84]. The crRNA and repair template sequences for all the strains generated by CRISPR-Cas9 editing in this study are provided in Table S5.

Embryonic viability assays and brood counts

For most measurements of embryonic viability, including all embryonic lethality suppression assays, L3-L4 larvae were picked individually to 35 mm MYOB agar plates at the indicated temperature and allowed to lay eggs for 1 day (20°C, 25°C), 2 days (16°C) or 3 days (12.5°C). The adult worms were removed, and the plates were incubated at the same temperature for an additional period of time equal to the egg-laying period. The number of dead and live progeny were then manually counted. For brood size measurements, L4 larvae were picked

individually to 35 mm MYOB agar plates. These plates were incubated at the indicated temperature and the adult transferred to a fresh plate every 24 hr until egg laying ceased. Live and dead progeny were counted on each plate 1 day (20°C, 25°C) or 2 days (16°C) after removing the adult.

RNAi

RNAi was administered by feeding as described previously [86]. In brief, animals at the L1 or L4 stage were transferred to a lawn of dsRNA-expressing bacteria that had been grown on MYOB plates supplemented with 50-100 µg/ml carbenicillin, with or without 25 µg/ml tetracycline and 1-2 mM IPTG (Isopropyl β- d-1-thiogalactopyranoside). Plates were then incubated at the specified temperature. RNAi against the nonessential *smd-1* gene served as a negative control.

Fixed and live imaging

Immunofluorescence microscopy was essentially performed as previously described [87]. The mouse monoclonal anti-alpha-tubulin antibody DM1A (Sigma-Aldrich, St. Louis, MO) and the rabbit anti-CeGrip1 antibody [64] were used at a dilution of 1:1000. Alexa 568 anti-mouse and Alexa 488 anti-rabbit secondary antibodies (Thermo Fisher Scientific, Waltham, MA) were used at a 1:1000 dilution. For detection of the SPOT tag, we used the SPOT-Label Alexa-Fluor 568 nanobody (Chromotek, Planegg-Martinsried, Germany) at a 1:1000 dilution. For time-lapse imaging of embryos, worms were grown at the indicated temperature and embryos dissected and mounted as described [87].

Spinning disk confocal microscopy of fixed specimens and whole live worms was performed using a Nikon Eclipse Ti2 microscope equipped with a Plan Apo 60X 1.2 N.A. water immersion lens, a CSU-X1 confocal scanning unit (Yokogawa Electric Corporation, Tokyo Japan), and a Prime 95B CMOS camera (Teledyne Photometrics, Tucson, AZ). Excitation light was generated using 405 nm, 488nm, and 561 nm solid state lasers housed in an LU-NV laser unit. NIS-Elements software (Nikon Instruments, Inc, Tokyo, Japan) was used for image acquisition.

Time-lapse spinning disk confocal imaging of live specimens was performed on a Nikon TE2000U inverted microscope equipped with a Plan Apo 60X 1.4 N.A. oil immersion lens, a Thermo Plate heating/cooling stage (Tokai Hit, Japan), a CSU10 confocal scanning unit (Yokogawa Electric Corporation, Tokyo, Japan) and a C9100-13 EM-CCD camera. (Hamamatsu Photonics, Shizuoka, Japan). Excitation light was generated using 405 nm, 491 nm, and 561 nm solid state lasers controlled via a LMM5 laser launch (Spectral Applied Research, Ontario, Canada) and fed through a Borealis beam conditioning unit (Spectral Applied Research, Ontario, Canada). Images were acquired using MetaMorph software (Molecular Devices San Jose, CA).

Image processing was performed with either NIS-Elements software (Nikon Instruments, Inc, Tokyo, Japan) or Fiji.

Immunoprecipitation-Mass Spectrometry

Whole worm extracts were prepared as described previously [88]. Eight milligrams of either *chd-1(bs122)* (control) or *chd-1(bs125)* (CHD-1::sfGFP) whole worm extracts and 80 microliters of GFP-Trap Magnetic Agarose beads (Chromotek)

were used for each IP. The IPs were performed at 4°C for 3 hours, washed twice with GFP-trap wash buffer (10 mM Tris-Cl pH 7.5, 150 mM NaCl, 0.5 mM EDTA), and suspended in 100 microliters of 1XTBS (50 mM Tris-Cl, pH 7.6, 150 mM NaCl). For mass spec, the samples were resuspended in a Tris/ Urea buffer, reduced, alkylated and digested with trypsin at 37°C overnight. This solution was subjected to solid phase extraction to concentrate the peptides and remove unwanted reagents followed by injection onto a Waters NanoAcquity HPLC equipped with a self-packed Aeris 3 µm C18 analytical column 0.075 mm by 20 cm, (Phenomenex, Torrance, CA). Peptides were eluted using standard reverse-phase gradients. The effluent from the column was analyzed using a Thermo Orbitrap Elite mass spectrometer (nanospray configuration) operated in a data dependent manner for 120 minutes. The resulting fragmentation spectra were correlated against the known database using PEAKS Studio 8.5 (Bioinformatic Solutions, Ontario, Canada) Scaffold Q+S (Proteome Software Inc., Portland, OR) was used to provide consensus reports for the identified proteins.

Auxin treatment

To deplete CDK-2, we employed the auxin-inducible degradation system [71]. Worms were grown on standard MYOB plates until they reached the L3 stage, at which point they were transferred to MYOB plates supplemented with 1mM indole-3-acetic acid (Alfa Aesar, Haverhill, MA) and seeded with *E. coli* OP50. Worms were grown for two days at 20° C before being processed for quantitative immunoblotting.

758

759 **Quantitative immunoblotting**

760   Samples for quantitative immunoblots were prepared from either whole
761 worm lysates or worm extracts. For whole worm lysates, 100 gravid adults were
762 washed twice with 1 ml of M9 buffer (22 mM KH₂PO₄, 22 mM Na₂HPO₄, 85 mM NaCl,
763 1 mM MgSO₄), resuspended in 40 µl of either NuPAGE LDS Sample Buffer
764 (Invitrogen, Waltham, MA) or 4X Laemmli buffer (Bio-Rad Laboratories, Inc.
765 Hercules, CA) and boiled at 95°C for 10 minutes. The lysates were stored at -30°C
766 prior to gel electrophoresis. For worm extracts, worms were grown on eight 100
767 mm MYOB agar plates until the bacteria was exhausted. The starved L1 larvae were
768 washed off the plates, transferred to 500 ml of liquid S-media containing *E.coli*
769 NA22, and grown at 20°C until they reached adulthood. Gravid worms were
770 collected, and extracts prepared as described [88]. The concentrations of the
771 extracts were determined using the Bio-Rad Protein assay kit (Bio-Rad Laboratories
772 Inc. Hercules, CA). The extracts were then aliquoted into individual tubes, flash
773 frozen in liquid nitrogen, and stored at -80°C.

774   SDS-PAGE gel electrophoresis was performed using 12 to 16 µl of lysate or
775 50 µg of extract per lane. Samples prepared in NuPAGE LDS Sample Buffer were
776 resolved on a Novex 4-12% Bis-Tris precast gels (Invitrogen, Waltham, MA) and
777 blotted to nitrocellulose using the iBlot semi-dry transfer system (Invitrogen,
778 Waltham, MA) according to the manufacturer's instructions. Samples prepared in 4X
779 Laemmli buffer were run on a 4-20% Mini-protean TGX precast gel (Bio-Rad
780 Laboratories, Hercules, CA) and transferred to nitrocellulose using the Trans-Blot

Turbo Transfer System (Bio-Rad Laboratories) according to the manufacturer's instructions. The membranes were blocked with Odyssey blocking buffer (LiCOR Biosciences, Lincoln, NE) and probed with a 1:1000 dilution of the following antibodies: anti-SPD-2 [41], anti-SAS-6 [29], anti-GFP (Roche, Indianapolis, IN), and anti-alpha-tubulin DM1A (Sigma-Aldrich, Inc). Anti-mouse 680 and anti-Rabbit 800 IRDye secondary antibodies (LiCOR Biosciences, Lincoln, NE) were used at a 1:14,000 dilution. Membranes were imaged using the Odyssey Clx imaging system (LiCOR Biosciences, Lincoln, NE). Quantitation of band intensities was performed using Fiji software [52] and normalized to the internal loading control.

RNA-Seq

RNA samples (four biological replicates per genotype) were prepared from N2 and *chd-1(bs122)* adult worms as described below for qRT-PCR. RNA quality was determined using an Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). All RNA samples had an RNA integrity number (RIN) greater than or equal to 9.5. Libraries were constructed using the NEB Next Ultra II RNA library prep for illumina per the manufacturer's protocol (New England Biolabs Inc., Ipswich, MA), and library concentrations measured using the 2100 Bioanalyzer. Libraries were pooled and sequenced on a HiSeq 2500 Sequencing System (Illumina, San Diego, CA), generating an average of 22 million reads for the N2 library (range 17-28 M reads) and an average of 23 million reads for the *chd-1(bs122)* library (range 21-26 M reads). FASTQ files were aligned to ce10 genome using BBMAP, Version 36.02. Gene count table, differential gene expression analysis and PCA analysis were performed using

the Genomatix Genome Analyzer (GGA)

[<https://www.genomatix.de/solutions/genomatix-genome-analyzer.html>].

qRT-PCR

Approximately 300 day-one adult (72 hours after plating as L1) animals were collected for RNA extraction by washing three times with M9 prior to suspension in 1mL Trizol Reagent (ThermoFisher Scientific #15596026). Nucleic acids were isolated via chloroform extraction and RNA was isolated with the Qiagen RNEasy Mini (Qiagen #74104) including on-column DNase I digestion. RNA was assessed for purity and concentration with a NanoDrop Lite. cDNA synthesis was performed with the iScript cDNA Synthesis Kit (Bio-Rad #1708891). qRT-PCR was performed with SYBR Select Master Mix (ThermoFisher #4472908) on a Bio-Rad CFX384 Touch Real-Time PCR Detection System (Bio-Rad # 1855485). Six biological replicates of each genotype were run in triplicate for each gene. Fold change was determined by the $\Delta\Delta\text{ct}$ method with Δct compared to *act-1*. A list of primer sequences used for qRT-PCR can be found in Table S6

Protein structure prediction and alignment

The protein structure of *C. elegans* CHD-1 was predicted using SWISS-MODEL [89-91]. Alignment of the predicted *C. elegans* and known yeast CHD-1 (PDB ID: 3MWY) [57] structures was performed using PyMOL software (The PyMOL Molecular Graphics System, Version 1.2r3pre, Schrödinger, LLC.).

Statistics and scatter plots

Statistical analysis and the generation of scatter plots were generated using Prism 8.3 (GraphPad Software, San Diego, CA). Differences in gene expression were assessed as parallel t-tests with a Holm-Sidak correction for multiple comparisons using the Graphpad Prism 8 platform.

Acknowledgements

We would like to thank Tony Hyman for generously providing the anti-CeGrip1 antibody, Yumi Kim for providing the *cdk-2::aid::3xflag* strain, and Jennifer Patterson-West for assisting with analysis of protein structure. Some strains were provided by the CGC, which is funded by the NIH Office of Research Infrastructure Programs (P40 OD010440), and by the National BioResource Project (Japan). This research was supported by the Intramural Research Program of the NIH, The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

Literature Cited

- 847
848
849
850
851
- 852 1. Schwarz A, Sankaralingam P, O'Connell KF, Muller-Reichert T (2018) Revisiting
853 Centrioles in Nematodes-Historic Findings and Current Topics. *Cells* 7 (8).
854 doi:10.3390/cells7080101
- 855 2. Nigg EA, Holland AJ (2018) Once and only once: mechanisms of centriole
856 duplication and their deregulation in disease. *Nat Rev Mol Cell Biol* 19 (5):297-312.
857 doi:10.1038/nrm.2017.127
- 858 3. Levine MS, Bakker B, Boeckx B, Moyett J, Lu J, Vitre B, Spierings DC, Lansdorp PM,
859 Cleveland DW, Lambrechts D, Foijer F, Holland AJ (2017) Centrosome Amplification
860 Is Sufficient to Promote Spontaneous Tumorigenesis in Mammals. *Dev Cell* 40
861 (3):313-322 e315. doi:10.1016/j.devcel.2016.12.022
- 862 4. Alkuraya FS (2015) Primordial dwarfism: an update. *Curr Opin Endocrinol*
863 *Diabetes Obes* 22 (1):55-64. doi:10.1097/MED.000000000000121
- 864 5. Barbelanne M, Tsang WY (2014) Molecular and cellular basis of autosomal
865 recessive primary microcephaly. *Biomed Res Int* 2014:547986.
866 doi:10.1155/2014/547986

- 867 6. Naveed M, Kazmi SK, Amin M, Asif Z, Islam U, Shahid K, Tehreem S (2018)
868 Comprehensive review on the molecular genetics of autosomal recessive primary
869 microcephaly (MCPH). Genet Res (Camb) 100:e7.
870 doi:10.1017/S0016672318000046

- 871 7. Arquint C, Nigg EA (2014) STIL microcephaly mutations interfere with APC/C-
872 mediated degradation and cause centriole amplification. Curr Biol 24 (4):351-360.
873 doi:10.1016/j.cub.2013.12.016

- 874 8. Marthiens V, Rujano MA, Pennetier C, Tessier S, Paul-Gilloteaux P, Basto R (2013)
875 Centrosome amplification causes microcephaly. Nat Cell Biol 15 (7):731-740.
876 doi:10.1038/ncb2746

- 877 9. Bettencourt-Dias M, Rodrigues-Martins A, Carpenter L, Riparbelli M, Lehmann L,
878 Gatt MK, Carmo N, Balloux F, Callaini G, Glover DM (2005) SAK/PLK4 is required for
879 centriole duplication and flagella development. Curr Biol 15 (24):2199-2207.
880 doi:10.1016/j.cub.2005.11.042

- 881 10. O'Connell KF, Caron C, Kopish KR, Hurd DD, Kempfues KJ, Li Y, White JG (2001)
882 The *C. elegans* zyg-1 gene encodes a regulator of centrosome duplication with
883 distinct maternal and paternal roles in the embryo. Cell 105 (4):547-558.
884 doi:10.1016/s0092-8674(01)00338-5

- 885 11. Shimanovskaya E, Viscardi V, Lesigang J, Lettman MM, Qiao R, Svergun DI, Round
886 A, Oegema K, Dong G (2014) Structure of the *C. elegans* ZYG-1 cryptic polo box
887 suggests a conserved mechanism for centriolar docking of Plk4 kinases. *Structure*
888 22 (8):1090-1104. doi:10.1016/j.str.2014.05.009
- 889 12. Delattre M, Canard C, Gonczy P (2006) Sequential protein recruitment in *C.*
890 *elegans* centriole formation. *Curr Biol* 16 (18):1844-1849.
891 doi:10.1016/j.cub.2006.07.059
- 892 13. Pelletier L, O'Toole E, Schwager A, Hyman AA, Muller-Reichert T (2006)
893 Centriole assembly in *Caenorhabditis elegans*. *Nature* 444 (7119):619-623.
894 doi:10.1038/nature05318
- 895 14. Kitagawa D, Vakonakis I, Olieric N, Hilbert M, Keller D, Olieric V, Bortfeld M, Erat
896 MC, Fluckiger I, Gonczy P, Steinmetz MO (2011) Structural basis of the 9-fold
897 symmetry of centrioles. *Cell* 144 (3):364-375. doi:10.1016/j.cell.2011.01.008
- 898 15. van Breugel M, Hirono M, Andreeva A, Yanagisawa HA, Yamaguchi S, Nakazawa
899 Y, Morgner N, Petrovich M, Ebong IO, Robinson CV, Johnson CM, Veprintsev D, Zuber
900 B (2011) Structures of SAS-6 suggest its organization in centrioles. *Science* 331
901 (6021):1196-1199. doi:10.1126/science.1199325
- 902 16. Lettman MM, Wong YL, Viscardi V, Niessen S, Chen SH, Shiau AK, Zhou H, Desai
903 A, Oegema K (2013) Direct binding of SAS-6 to ZYG-1 recruits SAS-6 to the mother

- 904 centriole for cartwheel assembly. Dev Cell 25 (3):284-298.
- 905 doi:10.1016/j.devcel.2013.03.011
- 906 17. Arquint C, Sonnen KF, Stierhof YD, Nigg EA (2012) Cell-cycle-regulated
- 907 expression of STIL controls centriole number in human cells. J Cell Sci 125 (Pt
- 908 5):1342-1352. doi:10.1242/jcs.099887
- 909 18. Habedanck R, Stierhof YD, Wilkinson CJ, Nigg EA (2005) The Polo kinase Plk4
- 910 functions in centriole duplication. Nat Cell Biol 7 (11):1140-1146.
- 911 doi:10.1038/ncb1320
- 912 19. Kleylein-Sohn J, Westendorf J, Le Clech M, Habedanck R, Stierhof YD, Nigg EA
- 913 (2007) Plk4-induced centriole biogenesis in human cells. Dev Cell 13 (2):190-202.
- 914 doi:10.1016/j.devcel.2007.07.002
- 915 20. Leidel S, Delattre M, Cerutti L, Baumer K, Gonczy P (2005) SAS-6 defines a
- 916 protein family required for centrosome duplication in C. elegans and in human cells.
- 917 Nat Cell Biol 7 (2):115-125. doi:10.1038/ncb1220
- 918 21. Peel N, Stevens NR, Basto R, Raff JW (2007) Overexpressing centriole-replication
- 919 proteins in vivo induces centriole overduplication and de novo formation. Curr Biol
- 920 17 (10):834-843. doi:10.1016/j.cub.2007.04.036

- 921 22. Tang CJ, Lin SY, Hsu WB, Lin YN, Wu CT, Lin YC, Chang CW, Wu KS, Tang TK
922 (2011) The human microcephaly protein STIL interacts with CPAP and is required
923 for procentriole formation. EMBO J 30 (23):4790-4804.
924 doi:10.1038/emboj.2011.378

- 925 23. Vulprecht J, David A, Tibelius A, Castiel A, Konotop G, Liu F, Bestvater F, Raab MS,
926 Zentgraf H, Izraeli S, Kramer A (2012) STIL is required for centriole duplication in
927 human cells. J Cell Sci 125 (Pt 5):1353-1362. doi:10.1242/jcs.104109

- 928 24. Zhang Y, Galardy PJ (2016) Ubiquitin, the centrosome, and chromosome
929 segregation. Chromosome Res 24 (1):77-91. doi:10.1007/s10577-015-9511-7

- 930 25. Ma L, Quigley I, Omran H, Kintner C (2014) Multicilin drives centriole biogenesis
931 via E2f proteins. Genes Dev 28 (13):1461-1471. doi:10.1101/gad.243832.114

- 932 26. Meraldi P, Lukas J, Fry AM, Bartek J, Nigg EA (1999) Centrosome duplication in
933 mammalian somatic cells requires E2F and Cdk2-cyclin A. Nat Cell Biol 1 (2):88-93.
934 doi:10.1038/10054

- 935 27. Miller JG, Liu Y, Williams CW, Smith HE, O'Connell KF (2016) The E2F-DP1
936 Transcription Factor Complex Regulates Centriole Duplication in Caenorhabditis
937 elegans. G3 (Bethesda) 6 (3):709-720. doi:10.1534/g3.115.025577

- 938 28. Mori M, Hazan R, Danielian PS, Mahoney JE, Li H, Lu J, Miller ES, Zhu X, Lees JA,
939 Cardoso WV (2017) Cytoplasmic E2f4 forms organizing centres for initiation of
940 centriole amplification during multiciliogenesis. Nat Commun 8:15857.
941 doi:10.1038/ncomms15857
- 942 29. Saavedra HI, Maiti B, Timmers C, Altura R, Tokuyama Y, Fukasawa K, Leone G
943 (2003) Inactivation of E2F3 results in centrosome amplification. Cancer Cell 3
944 (4):333-346. doi:10.1016/s1535-6108(03)00083-7
- 945 30. Trimarchi JM, Lees JA (2002) Sibling rivalry in the E2F family. Nat Rev Mol Cell
946 Biol 3 (1):11-20. doi:10.1038/nrm714
- 947 31. Marfella CG, Imbalzano AN (2007) The Chd family of chromatin remodelers.
948 Mutat Res 618 (1-2):30-40. doi:10.1016/j.mrfmmm.2006.07.012
- 949 32. Murawska M, Brehm A (2011) CHD chromatin remodelers and the transcription
950 cycle. Transcription 2 (6):244-253. doi:10.4161/trns.2.6.17840
- 951 33. Baumgart SJ, Najafova Z, Hossan T, Xie W, Nagarajan S, Kari V, Ditzel N, Kassem
952 M, Johnsen SA (2017) CHD1 regulates cell fate determination by activation of
953 differentiation-induced genes. Nucleic Acids Res 45 (13):7722-7735.
954 doi:10.1093/nar/gkx377

- 955 34. Krogan NJ, Kim M, Ahn SH, Zhong G, Kobor MS, Cagney G, Emili A, Shilatifard A,
956 Buratowski S, Greenblatt JF (2002) RNA polymerase II elongation factors of
957 *Saccharomyces cerevisiae*: a targeted proteomics approach. *Mol Cell Biol* 22
958 (20):6979-6992. doi:10.1128/mcb.22.20.6979-6992.2002

- 959 35. Lee Y, Park D, Iyer VR (2017) The ATP-dependent chromatin remodeler Chd1 is
960 recruited by transcription elongation factors and maintains H3K4me3/H3K36me3
961 domains at actively transcribed and spliced genes. *Nucleic Acids Res* 45 (12):7180-
962 7190. doi:10.1093/nar/gkx321

- 963 36. Park D, Shivram H, Iyer VR (2014) Chd1 co-localizes with early transcription
964 elongation factors independently of H3K36 methylation and releases stalled RNA
965 polymerase II at introns. *Epigenetics Chromatin* 7 (1):32. doi:10.1186/1756-8935-
966 7-32

- 967 37. Skene PJ, Hernandez AE, Groudine M, Henikoff S (2014) The nucleosomal barrier
968 to promoter escape by RNA polymerase II is overcome by the chromatin remodeler
969 Chd1. *Elife* 3:e02042. doi:10.7554/eLife.02042

- 970 38. Woodage T, Basrai MA, Baxevanis AD, Hieter P, Collins FS (1997)
971 Characterization of the CHD family of proteins. *Proc Natl Acad Sci U S A* 94
972 (21):11472-11477. doi:10.1073/pnas.94.21.11472

- 973 39. Biswas D, Dutta-Biswas R, Stillman DJ (2007) Chd1 and yFACT act in opposition
974 in regulating transcription. *Mol Cell Biol* 27 (18):6279-6287.
975 doi:10.1128/MCB.00978-07

- 976 40. Hennig BP, Bendrin K, Zhou Y, Fischer T (2012) Chd1 chromatin remodelers
977 maintain nucleosome organization and repress cryptic transcription. *EMBO Rep* 13
978 (11):997-1003. doi:10.1038/embor.2012.146

- 979 41. Walfridsson J, Khorosjutina O, Matikainen P, Gustafsson CM, Ekwall K (2007) A
980 genome-wide role for CHD remodelling factors and Nap1 in nucleosome
981 disassembly. *EMBO J* 26 (12):2868-2879. doi:10.1038/sj.emboj.7601728

- 982 42. Alen C, Kent NA, Jones HS, O'Sullivan J, Aranda A, Proudfoot NJ (2002) A role for
983 chromatin remodeling in transcriptional termination by RNA polymerase II. *Mol Cell*
984 10 (6):1441-1452. doi:10.1016/s1097-2765(02)00778-5

- 985 43. Jones HS, Kawauchi J, Braglia P, Alen CM, Kent NA, Proudfoot NJ (2007) RNA
986 polymerase I in yeast transcribes dynamic nucleosomal rDNA. *Nat Struct Mol Biol*
987 14 (2):123-130. doi:10.1038/nsmb1199

- 988 44. Ocampo J, Chereji RV, Eriksson PR, Clark DJ (2019) Contrasting roles of the RSC
989 and ISW1/CHD1 chromatin remodelers in RNA polymerase II elongation and
990 termination. *Genome Res* 29 (3):407-417. doi:10.1101/gr.242032.118

- 991 45. Zhou J, Li J, Serafim RB, Ketchum S, Ferreira CG, Liu JC, Coe KA, Price BD,
992 Yusufzai T (2018) Human CHD1 is required for early DNA-damage signaling and is
993 uniquely regulated by its N terminus. *Nucleic Acids Res* 46 (8):3891-3905.
994 doi:10.1093/nar/gky128

- 995 46. Boginya A, Detroja R, Matityahu A, Frenkel-Morgenstern M, Onn I (2019) The
996 chromatin remodeler Chd1 regulates cohesin in budding yeast and humans. *Sci Rep*
997 9 (1):8929. doi:10.1038/s41598-019-45263-3

- 998 47. Pray-Grant MG, Daniel JA, Schieltz D, Yates JR, 3rd, Grant PA (2005) Chd1
999 chromodomain links histone H3 methylation with SAGA- and SLIK-dependent
1000 acetylation. *Nature* 433 (7024):434-438. doi:10.1038/nature03242

- 1001 48. Flanagan JF, Mi LZ, Chruszcz M, Cymborowski M, Clines KL, Kim Y, Minor W,
1002 Rastinejad F, Khorasanizadeh S (2005) Double chromodomains cooperate to
1003 recognize the methylated histone H3 tail. *Nature* 438 (7071):1181-1185.
1004 doi:10.1038/nature04290

- 1005 49. Sims RJ, 3rd, Chen CF, Santos-Rosa H, Kouzarides T, Patel SS, Reinberg D (2005)
1006 Human but not yeast CHD1 binds directly and selectively to histone H3 methylated
1007 at lysine 4 via its tandem chromodomains. *J Biol Chem* 280 (51):41789-41792.
1008 doi:10.1074/jbc.C500395200

- 1009 50. Mills AA (2017) The Chromodomain Helicase DNA-Binding Chromatin
1010 Remodelers: Family Traits that Protect from and Promote Cancer. Cold Spring Harb
1011 Perspect Med 7 (4). doi:10.1101/cshperspect.a026450

- 1012 51. Gaspar-Maia A, Alajem A, Polesso F, Sridharan R, Mason MJ, Heidersbach A,
1013 Ramalho-Santos J, McManus MT, Plath K, Meshorer E, Ramalho-Santos M (2009)
1014 Chd1 regulates open chromatin and pluripotency of embryonic stem cells. Nature
1015 460 (7257):863-868. doi:10.1038/nature08212

- 1016 52. Ram O, Goren A, Amit I, Shores N, Yosef N, Ernst J, Kellis M, Gymrek M, Issner R,
1017 Coyne M, Durham T, Zhang X, Donaghey J, Epstein CB, Regev A, Bernstein BE (2011)
1018 Combinatorial patterning of chromatin regulators uncovered by genome-wide
1019 location analysis in human cells. Cell 147 (7):1628-1639.
1020 doi:10.1016/j.cell.2011.09.057

- 1021 53. Hatch EM, Kulukian A, Holland AJ, Cleveland DW, Stearns T (2010) Cep152
1022 interacts with Plk4 and is required for centriole duplication. J Cell Biol 191 (4):721-
1023 729. doi:10.1083/jcb.201006049

- 1024 54. Podhraski V, Campo-Fernandez B, Worle H, Piatti P, Niederegger H, Bock G,
1025 Fyodorov DV, Lusser A (2010) CenH3/CID incorporation is not dependent on the
1026 chromatin assembly factor CHD1 in Drosophila. PLoS One 5 (4):e10120.
1027 doi:10.1371/journal.pone.0010120

- 1028 55. O'Connell KF, Leys CM, White JG (1998) A genetic screen for temperature-
1029 sensitive cell-division mutants of *Caenorhabditis elegans*. *Genetics* 149 (3):1303-
1030 1321

- 1031 56. Lusser A, Urwin DL, Kadonaga JT (2005) Distinct activities of CHD1 and ACF in
1032 ATP-dependent chromatin assembly. *Nat Struct Mol Biol* 12 (2):160-166.
1033 doi:10.1038/nsmb884

- 1034 57. Hauk G, McKnight JN, Nodelman IM, Bowman GD (2010) The chromodomains of
1035 the Chd1 chromatin remodeler regulate DNA access to the ATPase motor. *Mol Cell*
1036 39 (5):711-723. doi:10.1016/j.molcel.2010.08.012

- 1037 58. Peel N, Iyer J, Naik A, Dougherty MP, Decker M, O'Connell KF (2017) Protein
1038 Phosphatase 1 Down Regulates ZYG-1 Levels to Limit Centriole Duplication. *PLoS*
1039 *Genet* 13 (1):e1006543. doi:10.1371/journal.pgen.1006543

- 1040 59. Decker M, Jaensch S, Pozniakovsky A, Zinke A, O'Connell KF, Zachariae W, Myers
1041 E, Hyman AA (2011) Limiting amounts of centrosome material set centrosome size
1042 in *C. elegans* embryos. *Curr Biol* 21 (15):1259-1267. doi:10.1016/j.cub.2011.06.002

- 1043 60. Lee JS, Garrett AS, Yen K, Takahashi YH, Hu D, Jackson J, Seidel C, Pugh BF,
1044 Shilatifard A (2012) Codependency of H2B monoubiquitination and nucleosome
1045 reassembly on Chd1. *Genes Dev* 26 (9):914-919. doi:10.1101/gad.186841.112

- 1046 61. Tran HG, Steger DJ, Iyer VR, Johnson AD (2000) The chromo domain protein
1047 chd1p from budding yeast is an ATP-dependent chromatin-modifying factor. EMBO J
1048 19 (10):2323-2331. doi:10.1093/emboj/19.10.2323

- 1049 62. Strnad P, Leidel S, Vinogradova T, Euteneuer U, Khodjakov A, Gonczy P (2007)
1050 Regulated HsSAS-6 levels ensure formation of a single procentriole per centriole
1051 during the centrosome duplication cycle. Dev Cell 13 (2):203-213.
1052 doi:10.1016/j.devcel.2007.07.004

- 1053 63. Kemp CA, Song MH, Addepalli MK, Hunter G, O'Connell K (2007) Suppressors of
1054 zyg-1 define regulators of centrosome duplication and nuclear association in
1055 Caenorhabditis elegans. Genetics 176 (1):95-113. doi:10.1534/genetics.107.071803

- 1056 64. Hannak E, Oegema K, Kirkham M, Gonczy P, Habermann B, Hyman AA (2002)
1057 The kinetically dominant assembly pathway for centrosomal asters in
1058 Caenorhabditis elegans is gamma-tubulin dependent. J Cell Biol 157 (4):591-602.
1059 doi:10.1083/jcb.200202047

- 1060 65. Furuta T, Joo HJ, Trimmer KA, Chen SY, Arur S (2018) GSK-3 promotes S-phase
1061 entry and progression in C. elegans germline stem cells to maintain tissue output.
1062 Development 145 (10). doi:10.1242/dev.161042

- 1063 66. Hinchcliffe EH, Li C, Thompson EA, Maller JL, Sluder G (1999) Requirement of
1064 Cdk2-cyclin E activity for repeated centrosome reproduction in *Xenopus* egg
1065 extracts. *Science* 283 (5403):851-854. doi:10.1126/science.283.5403.851

- 1066 67. Lacey KR, Jackson PK, Stearns T (1999) Cyclin-dependent kinase control of
1067 centrosome duplication. *Proc Natl Acad Sci U S A* 96 (6):2817-2822.
1068 doi:10.1073/pnas.96.6.2817

- 1069 68. Matsumoto Y, Hayashi K, Nishida E (1999) Cyclin-dependent kinase 2 (Cdk2) is
1070 required for centrosome duplication in mammalian cells. *Curr Biol* 9 (8):429-432.
1071 doi:10.1016/s0960-9822(99)80191-2

- 1072 69. Arquint C, Cubizolles F, Morand A, Schmidt A, Nigg EA (2018) The SKP1-Cullin-F-
1073 box E3 ligase betaTrCP and CDK2 cooperate to control STIL abundance and
1074 centriole number. *Open Biol* 8 (2). doi:10.1098/rsob.170253

- 1075 70. Kim DY, Roy R (2006) Cell cycle regulators control centrosome elimination
1076 during oogenesis in *Caenorhabditis elegans*. *J Cell Biol* 174 (6):751-757.
1077 doi:10.1083/jcb.200512160

- 1078 71. Zhang L, Ward JD, Cheng Z, Dernburg AF (2015) The auxin-inducible
1079 degradation (AID) system enables versatile conditional protein depletion in *C.*
1080 *elegans*. *Development* 142 (24):4374-4384. doi:10.1242/dev.129635

- 1081 72. Cunha-Ferreira I, Bento I, Pimenta-Marques A, Jana SC, Lince-Faria M, Duarte P,
1082 Borrego-Pinto J, Gilberto S, Amado T, Brito D, Rodrigues-Martins A, Debski J,
1083 Dzhindzhev N, Bettencourt-Dias M (2013) Regulation of autophosphorylation
1084 controls PLK4 self-destruction and centriole number. *Curr Biol* 23 (22):2245-2254.
1085 doi:10.1016/j.cub.2013.09.037

- 1086 73. Cunha-Ferreira I, Rodrigues-Martins A, Bento I, Riparbelli M, Zhang W, Laue E,
1087 Callaini G, Glover DM, Bettencourt-Dias M (2009) The SCF/Slimb ubiquitin ligase
1088 limits centrosome amplification through degradation of SAK/PLK4. *Curr Biol* 19
1089 (1):43-49. doi:10.1016/j.cub.2008.11.037

- 1090 74. Guderian G, Westendorf J, Uldschmid A, Nigg EA (2010) Plk4 trans-
1091 autophosphorylation regulates centriole number by controlling betaTrCP-mediated
1092 degradation. *J Cell Sci* 123 (Pt 13):2163-2169. doi:10.1242/jcs.068502

- 1093 75. Holland AJ, Fachinetti D, Zhu Q, Bauer M, Verma IM, Nigg EA, Cleveland DW
1094 (2012) The autoregulated instability of Polo-like kinase 4 limits centrosome
1095 duplication to once per cell cycle. *Genes Dev* 26 (24):2684-2689.
1096 doi:10.1101/gad.207027.112

- 1097 76. Holland AJ, Lan W, Niessen S, Hoover H, Cleveland DW (2010) Polo-like kinase 4
1098 kinase activity limits centrosome overduplication by autoregulating its own
1099 stability. *J Cell Biol* 188 (2):191-198. doi:10.1083/jcb.200911102

- 1100 77. Puklowski A, Homsy Y, Keller D, May M, Chauhan S, Kossatz U, Grunwald V,
1101 Kubicka S, Pich A, Manns MP, Hoffmann I, Gonczy P, Malek NP (2011) The SCF-
1102 FBXW5 E3-ubiquitin ligase is regulated by PLK4 and targets HsSAS-6 to control
1103 centrosome duplication. Nat Cell Biol 13 (8):1004-1009. doi:10.1038/ncb2282

- 1104 78. Rogers GC, Rusan NM, Roberts DM, Peifer M, Rogers SL (2009) The SCF Slimb
1105 ubiquitin ligase regulates Plk4/Sak levels to block centriole reduplication. J Cell Biol
1106 184 (2):225-239. doi:10.1083/jcb.200808049

- 1107 79. Peel N, Dougherty M, Goeres J, Liu Y, O'Connell KF (2012) The C. elegans F-box
1108 proteins LIN-23 and SEL-10 antagonize centrosome duplication by regulating ZYG-1
1109 levels. J Cell Sci 125 (Pt 15):3535-3544. doi:10.1242/jcs.097105

- 1110 80. Capecchi MR, Pozner A (2015) ASPM regulates symmetric stem cell division by
1111 tuning Cyclin E ubiquitination. Nat Commun 6:8763. doi:10.1038/ncomms9763

- 1112 81. Hsu J, Sage J (2016) Novel functions for the transcription factor E2F4 in
1113 development and disease. Cell Cycle 15 (23):3183-3190.
1114 doi:10.1080/15384101.2016.1234551

- 1115 82. Brenner S (1974) The genetics of Caenorhabditis elegans. Genetics 77 (1):71-94

- 1116 83. Iyer J, DeVaul N, Hansen T, Nebenfuehr B (2019) Using Microinjection to
1117 Generate Genetically Modified *Caenorhabditis elegans* by CRISPR/Cas9 Editing.
1118 *Methods Mol Biol* 1874:431-457. doi:10.1007/978-1-4939-8831-0_25

- 1119 84. Paix A, Folkmann A, Rasoloson D, Seydoux G (2015) High Efficiency, Homology-
1120 Directed Genome Editing in *Caenorhabditis elegans* Using CRISPR-Cas9
1121 Ribonucleoprotein Complexes. *Genetics* 201 (1):47-54.
1122 doi:10.1534/genetics.115.179382

- 1123 85. Arribere JA, Bell RT, Fu BX, Artiles KL, Hartman PS, Fire AZ (2014) Efficient
1124 marker-free recovery of custom genetic modifications with CRISPR/Cas9 in
1125 *Caenorhabditis elegans*. *Genetics* 198 (3):837-846.
1126 doi:10.1534/genetics.114.169730

- 1127 86. Kamath RS, Ahringer J (2003) Genome-wide RNAi screening in *Caenorhabditis*
1128 *elegans*. *Methods* 30 (4):313-321. doi:10.1016/s1046-2023(03)00050-1

- 1129 87. O'Connell KF, Golden A (2014) Confocal imaging of the microtubule cytoskeleton
1130 in *C. elegans* embryos and germ cells. *Methods Mol Biol* 1075:257-272.
1131 doi:10.1007/978-1-60761-847-8_13

- 1132 88. Zanin E, Dumont J, Gassmann R, Cheeseman I, Maddox P, Bahmanyar S, Carvalho
1133 A, Niessen S, Yates JR, 3rd, Oegema K, Desai A (2011) Affinity purification of protein

- 1134 complexes in *C. elegans*. *Methods Cell Biol* 106:289-322. doi:10.1016/B978-0-12-
1135 544172-8.00011-6
- 1136 89. Bienert S, Waterhouse A, de Beer TA, Tauriello G, Studer G, Bordoli L, Schwede T
1137 (2017) The SWISS-MODEL Repository-new features and functionality. *Nucleic Acids*
1138 *Res* 45 (D1):D313-D319. doi:10.1093/nar/gkw1132
- 1139 90. Guex N, Peitsch MC, Schwede T (2009) Automated comparative protein
1140 structure modeling with SWISS-MODEL and Swiss-PdbViewer: a historical
1141 perspective. *Electrophoresis* 30 Suppl 1:S162-173. doi:10.1002/elps.200900140
- 1142 91. Waterhouse A, Bertoni M, Bienert S, Studer G, Tauriello G, Gumienny R, Heer FT,
1143 de Beer TAP, Rempfer C, Bordoli L, Lepore R, Schwede T (2018) SWISS-MODEL:
1144 homology modelling of protein structures and complexes. *Nucleic Acids Res* 46
1145 (W1):W296-W303. doi:10.1093/nar/gky427
1146
1147

Figure Legends

Figure 1. Deletion of the *chd-1* gene partially rescues the embryonic lethality and centrosome duplication defect of the *zyg-1(it25)* mutant. (A) Schematic of the wild-type CHD-1 protein and protein products of alleles used in this study. (B) Suppression of embryonic lethality of *zyg-1(it25)* mutants by the original allele *chd-1(ok2798)*. Each data point represents the percentage of viable progeny from a single hermaphrodite. Bars indicate mean and standard deviation. *** $p < 0.0001$ as calculated by Chi squared analysis (C) An immunoblot showing that the *chd-1(bs122)* allele drives expression of GFP. (D) The *chd-1(bs122)* allele partially suppresses the embryonic lethality of the *zyg-1(it25)* mutant. Each data point represents the percentage of viable progeny from a single hermaphrodite. Bars indicate mean and standard deviation. *** $p < 0.0001$ as calculated by Chi squared analysis. (E) Loss of CHD-1 partially suppresses the centrosome duplication defect of the *zyg-1(it25)* mutant. The graph depicts the number of centrosome duplication failures or successes as determined by live cell imaging of *zyg-1(it25)* and *chd-1(bs185); zyg-1(it25)* embryos expressing GFP::histone and SPD-2::mCherry. ** $p < 0.001$ as calculated by Fisher's Exact Test. (F). Frames from select time-lapse imaging data sets of *zyg-1(it25)* and *chd-1(bs185); zyg-1(it25)* embryos expressing GFP::Histone and SPD-2::mCherry. Arrowheads indicate centrosomes. Scale bar = 10 μm .

Figure 2. The *chd-1* gene is broadly transcribed in *C. elegans*, but its protein product is down-regulated in the proximal germ line and early embryo. (A) Schematic of the protein products of the wild-type *chd-1* gene and two gfp-tagged alleles. The *chd-1(bs125)* allele encodes a wild-type CHD-1 protein C-terminally tagged with GFP. The *chd-1(bs123)* allele is identical to *chd-1(bs125)* except that it possesses a missense mutation in the helicase domain. (B) Images of hermaphrodites expressing GFP (top) and CHD-1::GFP (bottom) driven by the 5' and 3' *chd-1* flanking regions. Both GFP and CHD-1::GFP are broadly expressed in the soma and germ line but unlike GFP, CHD-1::GFP is concentrated in nuclei throughout all tissues except those of the proximal germ line and early embryo. The distal germ line (d), proximal germ line (p), and early embryos (e) are indicated. Insets show enlarged view of these tissues. (C) Immunoblot probed with an anti-GFP antibody showing that the wild-type and mutant CHD-1::GFP proteins are expressed at about the same level. (D) CHD-1::GFP but not CHD-1(D538N) is functional. The *chd-1(bs125)* and *chd-1(bs123)* alleles were tested for suppression of the *zyg-1(it25)* embryonic lethal phenotype. Unlike the null *chd-1(bs122)* allele, the *chd-1(bs125)* allele fails to suppress *zyg-1(it25)*, demonstrating that CHD-1::GFP is functional. The *chd-1(bs123)* allele suppresses *zyg-1(it25)* indicating that helicase activity is essential for regulating centriole duplication. *** $p < 0.0001$ as calculated by an unpaired t test with Welch's correction. (E) Super imposition of the predicted structure of *C. elegans* CHD-1 protein (green) with that of the *S. cerevisiae* Chd1 protein (gray, accession 3MWY). The inset shows an enlargement focusing on the region proximal to aspartate 513 of yeast Chd1 (blue) aligned with aspartate 538 of worm CHD-1 (orange).

Figure 3. Loss of CHD-1 results in over-expression of SPD-2 and SAS-6. (A) Quantitative immunoblot comparing SPD-2 levels in wild-type and *chd-1* mutants. Note the nearly two-fold increase in the *chd-1(bs122)* deletion strains as compared to the wild-type strain. (B) Quantitative immunoblot comparing SAS-6 levels in control (*chd-1(bs122)/+* heterozygotes) and *chd-1(bs122)* homozygotes. (C) Quantitation of SPD-2 and SAS-6 levels as determined by immunoblotting. (D) Quantitative fluorescence microscopy of a *gfp::spd-2* transgene in *chd-1(bs122)* heterozygous (control) and homozygous embryos. As shown in the schematic, the transgene is expressed under control of the *pie-1* promoter and 3' utr and its expression is negatively affected by loss of CHD-1. Representative images (left, scale bar = 10 μ m) and quantitation (right) are shown. Each dot represents a single centrosome. Bars indicate mean and standard deviation. *** $p < 0.0001$, unpaired t test with Welch's correction. (E) Quantitative immunoblot of endogenous SPD-2 and GFP::SPD-2 levels in *chd-1(bs122)* heterozygotes and homozygotes. Note that endogenous SPD-2 is elevated almost two-fold in the *chd-1(bs122)* homozygotes relative to heterozygous siblings, while the level of GFP::SPD-2 is lower. (F) Quantitative fluorescence microscopy of a *spd-2::mCherry* transgene in heterozygous and homozygous embryos. As shown in the schematic, the transgene is expressed under control of the native *spd-2* promoter and 3' utr, and its expression is positively affected by loss of CHD-1. Representative images (left, scale bar = 10 μ m) and quantitation (right) are shown. Each dot represents a single centrosome. Bars indicate mean and standard deviation. * $p < 0.05$, unpaired t test with Welch's correction.

Figure 4. *cdk-2* transcript levels are elevated in *chd-1(bs122)* mutants. (A) List of genes whose mRNA levels are affected by two-fold or greater by loss of CHD-1 as determined by RNA-Seq. (B) Results of qRT-PCR of adult wild-type and *chd-1(bs122)* worms showing relative transcript levels. *** $p < 0.0001$, t-test with a Holm-Sidak correction

Figure 5. CHD-1 and DPL-1 cooperate to control SAS-6 levels and proper centriole number. (A) Suppression of the embryonic lethal phenotype of *zyg-1(it25)* at 24° in the presence of the *chd-1(bs122)* allele and/or *dpl-1(RNAi)*. Wild-type alleles are indicated by a plus sign while mutant alleles are indicated by either *it25* or a minus sign. Each data point represents the percentage of viable progeny from a single hermaphrodite. Bars indicate mean and standard deviation. Note that the level of suppression observed in presence of both *chd-1(bs122)* and *dpl-1(RNAi)* is greater than the expected level of suppression if the effects of *chd-1(bs122)* and *dpl-1(RNAi)* were additive. (B) The simultaneous depletion of CHD-1 and DPL-1 results in embryonic lethality. *dpl-1(RNAi)* or control RNAi (*smd-1*) were performed in a wild-type or *chd-1(bs122)* background. Specifically, the combination of *chd-1(bs122)* and *dpl-1(RNAi)* led to embryonic lethality. Bars indicate mean and standard deviation. (C). The *chd-1(bs122)* deletion allele enhances the embryonic lethality of *dpl-1(bs169)*. Embryonic viability was measured at the indicated temperatures in *chd-1(bs122)*, *dpl-1(bs169)*, and *chd-1(bs122); dpl-1(bs169)* strains. While the *chd-1(bs122)* strain was fully viable at all temperatures, the *dpl-1(bs169)* and *chd-1(bs122); dpl-1(bs169)* strains displayed embryonic lethality that became progressively more severe as the temperature was reduced. At all temperatures tested, the *chd-1(bs122); dpl-1(bs169)* double mutant exhibited a more

severe phenotype than the *dpl-1(bs169)* single mutant. Bars indicate mean and standard deviation. (E) The *dpl-1(bs169)* and *chd-1(bs122); dpl-1(bs169)* embryos grown at 12.5° were immunostained for alpha-tubulin (red), CeGrip-1 (green) and DNA (blue). Images show two-cell stage embryos harboring extra centrosomes. Scale bar = 10 μm.

Figure 6. CDK-2 is required for *dpl-1* and *chd-1*-mediated suppression of *zyg-1*. (A) Percent embryonic lethality among the progeny of wild-type and *zyg-1(it25) dpl-1(bs21)* strains following *smd-1* (control) and *cdk-2* RNAi. The progeny of wild-type animals subjected to *cdk-2(RNAi)* exhibit a small reduction in viability. In contrast, viability among the progeny of *zyg-1(it25) dpl-1(bs21)* animals subjected to *cdk-2(RNAi)* is almost completely lost, indicating that CDK-2 plays an important role in *dpl-1*-mediated suppression. *** $p < 0.0001$, two-tailed t test with Welch's correction. (B) Percent embryonic lethality in wild-type and *chd-1(bs122); zyg-1(it25)* strains following *smd-1* (control) and *cdk-2* RNAi. The progeny of wild-type animals subjected to *cdk-2(RNAi)* exhibit a small but insignificant reduction in viability. In contrast, viability among the progeny of *zyg-1(it25) dpl-1(bs21)* animals subjected to *cdk-2(RNAi)* is significantly reduced, indicating that CDK-2 plays an important role in *chd-1*-mediated suppression. ** $p < 0.001$, ns= not significant, two-tailed t test with Welch's correction. (C) Immunoblot of whole *cdk-2::aid; TIR-1::mRuby* worms probed for SAS-6 and α-tubulin. The SAS-6 band is identified by its size (56 kDa) and its reduction in intensity upon *sas-6(RNAi)*. *smd-1(RNAi)* serves as a negative control. The presence or absence of auxin in the growth media is indicated. (D) Quantitation of immunoblots of *cdk-2::aid; TIR-1::mRuby* worms probed for SAS-6. (E) Model of regulatory scheme. In germ line

1261 nuclei, EFL-1/DPL-1 and CHD-1 independently down regulate expression of the *cdk-2*
 1262 gene. CDK-2 protein in turn promotes the expression of SAS-6. Under normal
 1263 conditions, this pathway ensures that oocytes, and ultimately embryos, inherit the proper
 1264 amount of SAS-6 to support centriole duplication during the embryonic cell divisions.
 1265

A **B** **C** **D** **E**

Figure 1

A **B** **E** **C** **D**

Figure 2

Figure 3

A

Genes strongly affected by loss of CHD-1		
Gene	Log ₂ (Fold Change)	Expression Ratio (<i>chd-1</i> (Δ)/wt)
<i>clec-47</i>	1.427	2.7
<i>pgp-7</i>	1.356	2.6
<i>pgp-6</i>	1.223	2.3
<i>sodh-1</i>	1.103	2.1
<i>gst-4</i>	1.084	2.1
C26H9A.2	1.038	2.1
<i>gtl-1</i>	1.038	2.1
K10C2.3	1.003	2.0
<i>plk-3</i>	-2.155	0.25
<i>fbxa-192</i>	-1.933	0.26
<i>sax-2</i>	-1.362	0.38

bioRxiv preprint doi: <https://doi.org/10.1101/2021.09.02.458660>; this version posted September 3, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

B

Figure 4

Figure 5

Figure 6